Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Owen A. O’Connor(Virginia Cancer Institute), Juliana Pereira(Universidade de São Paulo), Carlos Chiattone(Hospital Samaritano de São Paulo), Francesco d’Amore(Aarhus University), Emily Sheldon‐Waniga(Millennium Engineering and Integration (United States)), Eric D. Hsi(Mayo Clinic), Judit Demeter(Semmelweis University), John P. Leonard(New York University), Karthik Venkatakrishnan(Ono Pharmaceutical (United States)), Claudio Dansky Ullmann(Multimeric Biotherapeutics (United States)), Francine M. Foss(Yale Cancer Center), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), Nelson Hamerschlak(Hospital Israelita Albert Einstein), Andrei R. Shustov(Seattle Cancer Care Alliance), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), E. Jane Leonard(Millennium Engineering and Integration (United States)), Judith Trotman(The University of Sydney), Eric D. Jacobsen(Dana-Farber Cancer Institute), Muhıt Özcan(Ankara University), Anne Beaven(Duke Medical Center), Tamás Masszi, Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Hua Liu(Millennium Engineering and Integration (United States)), Mehmet Turgut(Hospital Universitari i Politècnic La Fe), Won-Seog Kim(Samsung Medical Center), Anne Lennard, Dolores Caballero(Complejo Hospitalario de Salamanca), Josep M. Roncero(Institut Català d'Oncologia), Lorenz Trümper(University of Göttingen)
Journal of Clinical Oncology
February 1, 2019
Cited by 154


Related Papers